Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial
Lang A, de Havenon A, Mac Grory B, Henninger N, Shu L, Furie K, Easton J, Kim A, Johnston S, Yaghi S. Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. European Stroke Journal 2022, 8: 328-333. PMID: 37021190, PMCID: PMC10069178, DOI: 10.1177/23969873221148224.Peer-Reviewed Original ResearchConceptsSubsequent ischemic strokeEffect of clopidogrelSubsequent stroke riskIschemic strokeMajor hemorrhagePoint trialStroke riskSmoking statusMinor Ischemic Stroke (POINT) trialSubgroup interaction analysesMultivariable Cox regressionMinor ischemic strokeIschemic stroke trialsEffect of smokingNon-significant trendNew TIACurrent smokersStroke trialsTobacco smokingCox regressionIndex eventSmokersSecondary analysisClopidogrelStrokeDirect Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
Yaghi S, Saldanha IJ, Misquith C, Zaidat B, Shah A, Joudi K, Persaud B, Khalek F, Shu L, de Havenon A, Mistry EA, Bakradze E, Goldstein ED, Reagan J, Theodorou A, Palaiodimou L, Furie K, Field TS, Tsivgoulis G, Mac Grory B. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022, 53: 3014-3024. PMID: 35938419, DOI: 10.1161/strokeaha.122.039579.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVitamin K antagonistsVenous thrombosisK antagonistsSystematic reviewRelative riskObservational studyDirect Oral Anticoagulants Versus Vitamin K AntagonistsSafety of DOACsVitamin K antagonist treatmentRecurrent venous thromboembolismHigh-level evidenceLeast moderate riskVenous recanalizationOral anticoagulantsVenous thromboembolismMajor hemorrhageMore patientsAntagonist treatmentIntracranial hemorrhageCombination of keywordsComparable efficacyInclusion criteriaSafety outcomes